Additional file 1. Sequences of oligonucleotides and probes.Nucleotide sequences and labeling of all oligonucleotides and probes used in this study
Additional file 1: Table S1. A list of CCAs/NCCAs and their copy number variation in U251, U251TMZ1 ...
Frequent discrepancies between preclinical and clinical results of anticancer agents demand a reliab...
SummaryFrequent discrepancies between preclinical and clinical results of anticancer agents demand a...
Additional file 3. Overview of highest in vivo passages of engrafted samples. Given numbers indicate...
Additional file 1: Supplementary data including Supplementary Methods, 1 Supplementary Table, 4 Supp...
Additional file 1: Table S1. Clinical information of PDXs used for TIL studies. Table S2. Clinical i...
Additional file 1: Figure S1. GeneTrails comprehensive solid tumor panel. Table S1. List of Genomic ...
Additional file 10. This word document contains descriptions and additional information regarding th...
Glioblastoma (GBM) heterogeneity in the genomic and phenotypic properties has potentiated personaliz...
Additional file 1: Table S1. Oligonucleotide sequences used for synthesis of DNA fragments for homol...
Additional file 2. LaTeX code used to generate the BERG trial protocol. This is provided so that oth...
Additional file 1: Numerical tabulation of profiles of Tom20 and GAPDH after normalization and align...
There is a compelling need for new therapeutic strategies for glioblastoma multiforme (GBM). Preclin...
Additional file 1: Table S1. Quality control metrics of targeted sequencing data. Table S2. Quality ...
Additional file 1: Table S1. Summary of whole exome sequencing data quality control for patient-deri...
Additional file 1: Table S1. A list of CCAs/NCCAs and their copy number variation in U251, U251TMZ1 ...
Frequent discrepancies between preclinical and clinical results of anticancer agents demand a reliab...
SummaryFrequent discrepancies between preclinical and clinical results of anticancer agents demand a...
Additional file 3. Overview of highest in vivo passages of engrafted samples. Given numbers indicate...
Additional file 1: Supplementary data including Supplementary Methods, 1 Supplementary Table, 4 Supp...
Additional file 1: Table S1. Clinical information of PDXs used for TIL studies. Table S2. Clinical i...
Additional file 1: Figure S1. GeneTrails comprehensive solid tumor panel. Table S1. List of Genomic ...
Additional file 10. This word document contains descriptions and additional information regarding th...
Glioblastoma (GBM) heterogeneity in the genomic and phenotypic properties has potentiated personaliz...
Additional file 1: Table S1. Oligonucleotide sequences used for synthesis of DNA fragments for homol...
Additional file 2. LaTeX code used to generate the BERG trial protocol. This is provided so that oth...
Additional file 1: Numerical tabulation of profiles of Tom20 and GAPDH after normalization and align...
There is a compelling need for new therapeutic strategies for glioblastoma multiforme (GBM). Preclin...
Additional file 1: Table S1. Quality control metrics of targeted sequencing data. Table S2. Quality ...
Additional file 1: Table S1. Summary of whole exome sequencing data quality control for patient-deri...
Additional file 1: Table S1. A list of CCAs/NCCAs and their copy number variation in U251, U251TMZ1 ...
Frequent discrepancies between preclinical and clinical results of anticancer agents demand a reliab...
SummaryFrequent discrepancies between preclinical and clinical results of anticancer agents demand a...